Tetralogic Pharmaceuticals (TLOG) vs. Anavex Life Sciences (NASDAQ:AVXL) Head-To-Head Survey

Anavex Life Sciences (NASDAQ: AVXL) and Tetralogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Risk & Volatility

Anavex Life Sciences has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Anavex Life Sciences and Tetralogic Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 2 0 3.00
Tetralogic Pharmaceuticals 0 0 0 0 N/A

Anavex Life Sciences presently has a consensus price target of $14.50, suggesting a potential upside of 322.74%. Given Anavex Life Sciences’ higher possible upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Tetralogic Pharmaceuticals.

Valuation & Earnings

This table compares Anavex Life Sciences and Tetralogic Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$13.46 million ($0.33) -10.39
Tetralogic Pharmaceuticals N/A N/A -$49.72 million ($1.64) -0.07

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Tetralogic Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

22.7% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 0.0% of Tetralogic Pharmaceuticals shares are owned by institutional investors. 11.6% of Anavex Life Sciences shares are owned by insiders. Comparatively, 15.4% of Tetralogic Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.


This table compares Anavex Life Sciences and Tetralogic Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -70.10% -63.39%
Tetralogic Pharmaceuticals N/A N/A N/A

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases. The Company’s SIGMACEPTOR Discovery Platform produced small molecule drug candidates with unique modes of action. Sigma receptors may be targets for therapeutics to combat many human diseases, including Alzheimer’s disease. When bound by the appropriate ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin or development) of disease.

Tetralogic Pharmaceuticals Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply